Stay updated with breaking news from Meredith Chuk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Of the dozens of patients Dr. Jim Yates has treated for COVID-19 at his long-term care center in rural Alabama, this one made him especially nervous.
Critics say a change in federal policy limits supplies for the vulnerable population of frail and elder residents.
Share this article Share this article HOUSTON, June 1, 2021 /PRNewswire/ -- Houston Methodist announced today, in partnership with the U.S. Department of Health and Human Services (HHS), that it has expanded access to COVID-19 monoclonal antibody therapy (mAb) in the Greater Houston area. The promising treatment has been shown to keep high-risk COVID-19 patients out of the hospital and reduce the likelihood of progression to severe disease. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses. If administered ...
The Barnstable Patriot HYANNIS — Cape Cod Hospital, in partnership with the Commonwealth of Massachusetts Department of Public Health (DPH) and the U.S. Department of Health and Human Services (HHS), announced Wednesday that it has expanded access to monoclonal antibody therapy (mAb) and will administer the treatment at a new mobile unit at the hospital. Positioned near the COVID -19 testing site, the temporary clinic will help patients that have tested positive for COVID-19 receive immediate treatment. The promising mAb therapy has been shown to keep high-risk COVID-19 patients out of the ...
E-Mail Houston Methodist announced today, in partnership with the U.S. Department of Health and Human Services (HHS), that it has expanded access to COVID-19 monoclonal antibody therapy (mAb) in the Greater Houston area. The promising treatment has been shown to keep high-risk COVID-19 patients out of the hospital and reduce the likelihood of progression to severe disease. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses. If administered within 10 days of onset of COVID-19 symptoms, the one-time therapy ...